Dasatinib, a selective tyrosine kinase inhibitor, prevents joint destruction in rheumatoid arthritis animal model

Abstract

AbstractAimWe aimed to evaluate the preventive role of the tyrosine kinase inhibitor dasatinib in an animal model of rheumatoid arthritis (RA).MethodsDBA/1J mice were injected with bovine type II collagen to induce arthritis (collagen‐induced arthritis [CIA]). There were four experimental groups of mice, namely negative control (non‐CIA), vehicle‐treated CIA, dasatinib‐pretreated CIA, and dasatinib‐treated CIA. After collagen immunization, arthritis progression in the mice was clinically scored twice weekly for 5 weeks. Flow cytometry was used to evaluate in vitro CD4+ T‐cell differentiation and ex vivo mast cell/CD4+ T‐cell differentiation. Osteoclast formation was evaluated using tartrate‐resistant acid phosphatase (TRAP) staining and by estimating the resorption pit area.ResultsWe found that the clinical arthritis histological scores were lower in the dasatinib pretreatment group than in the vehicle and dasatinib post‐treatment groups. Flow cytometry showed that FcεR1+ cells were downregulated and regulatory T cells were upregulated in splenocytes of the dasatinib pretreatment group compared with those in the vehicle group. Additionally, there was a decline in IL‐17+ CD4+ T‐cell differentiation and an increase in CD4+ CD24high Foxp3+ T‐cell differentiation with in vitro dasatinib treatment of human CD4+ T cells. The number of TRAP+ osteoclasts and the area of the resorption were decreased in the bone marrow cells derived from dasatinib‐pretreated mice compared with those derived from vehicle group.ConclusionDasatinib protected against arthritis in an animal model of RA by regulating the differentiation of regulatory T cells and IL‐17+ CD4+ T cells and inhibiting osteoclastogenesis, indicating the therapeutic potential of dasatinib in the treatment of early RA.